Sykehuset Innlandet HF   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Brumunddal Norway (2001)

Organization Overview

First Clinical Trial
2001
NCT00257790
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Innlandet Hospital, Norway | Innlandet Hospital Trust Lillehammer | Innlandet Hospital Trust Lillehammer, Neurological Department | Innlandet Hospital Trust, Postboks 104, 2381 Brumunddal, Norway | Innlandet Hospital Trust, Reinsvoll | Innlandet Hospital Trust, Sanderud | Medi 3 Innlandet AS, avd Hamar | Sykehuset Innlandet HF | Tor A. Strand

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aggression (Phase 3)

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Breast Neoplasms (Phase 2)

Bronchiolitis (Phase 4)

Dementia (Phase 4)

Depression, Postpartum (Phase 3)

Diarrhea (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis E (Phase 4)

Infections (Phase 4)

Irritable Bowel Syndrome (Phase 2)

Leg Ulcer (Phase 2)

Multiple Sclerosis (Phase 3)

Neutropenia (Phase 4)

Pneumonia (Phase 2)

Psychomotor Agitation (Phase 3)

Puerperal Disorders (Phase 3)

Sclerosis (Phase 3)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Vitamin B 12 Deficiency (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 23
  • # of Trial APIs: 34